What Is the Active Ingredient in Mounjaro? Understanding Tirzepatide's Dual-Receptor Mechanism and Why It Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro's active ingredient is tirzepatide, a synthetic peptide that activates both GLP-1 and GIP receptors, making it the first dual agonist approved for type 2 diabetes and obesity
• The dual-receptor mechanism produces 20 to 25% greater weight loss than GLP-1-only medications like semaglutide in head-to-head trials
• Tirzepatide has a 39-amino-acid structure with specific modifications at positions 2 and 20 that prevent enzyme breakdown and extend half-life to 5 days
• The same active ingredient appears in both brand-name Mounjaro (for diabetes) and Zepbound (for weight loss), differing only in FDA-approved indication and dosing schedule

Direct answer (40-60 words)

Mounjaro's active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It's a 39-amino-acid synthetic peptide that mimics two naturally occurring incretin hormones. Tirzepatide is the first medication to activate both receptor pathways simultaneously, producing greater metabolic effects than GLP-1-only medications like semaglutide.

Table of contents

1. The molecular structure: what tirzepatide actually is
2. The dual-receptor mechanism: why GIP + GLP-1 matters
3. How tirzepatide differs from semaglutide at the molecular level
4. The clinical data: dual agonism vs single-receptor activation
5. What most articles get wrong about "active ingredient"
6. Mounjaro vs Zepbound: same ingredient, different indication
7. The compounded tirzepatide question: is it the same molecule?
8. The manufacturing process: from synthesis to injection
9. Why the C-20 fatty acid chain matters for dosing schedule
10. The decision framework: when dual-receptor activation makes sense
11. FAQ
12. Sources

The molecular structure: what tirzepatide actually is

Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813 daltons. The base structure mimics natural GIP (glucose-dependent insulinotropic polypeptide), one of two incretin hormones the gut releases after eating.

The molecule has three critical modifications that distinguish it from natural GIP:

1. Alanine substitution at position 2. Natural GIP degrades rapidly because the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves the bond between positions 2 and 3. Replacing the natural amino acid with alanine blocks DPP-4 activity, extending the molecule's lifespan from minutes to days.

1. C-20 fatty diacid chain attached at position 20. This lipid chain binds to albumin in the bloodstream, creating a depot effect that slows absorption and clearance. The same modification appears in insulin degludec and semaglutide. The chain extends tirzepatide's half-life to approximately 5 days, enabling once-weekly dosing.

1. GLP-1 receptor binding domain. While the base structure resembles GIP, specific amino acid sequences allow tirzepatide to activate GLP-1 receptors at clinically meaningful levels. This dual activation is the defining feature that separates tirzepatide from every other incretin-based medication.

The chemical formula is C₂₂₅H₃₄₈N₅₆O₆₈. The molecule is produced through recombinant DNA technology in engineered Escherichia coli bacteria, then purified and formulated with excipients for subcutaneous injection.

The dual-receptor mechanism: why GIP + GLP-1 matters

The human incretin system has two primary hormones: GLP-1 and GIP. Both are released by intestinal cells in response to food, but they activate different receptor pathways with overlapping and complementary effects.

GLP-1 receptor activation:

• Slows gastric emptying (food stays in stomach longer)
• Suppresses glucagon release from pancreatic alpha cells
• Increases insulin secretion in response to glucose
• Reduces appetite through central nervous system pathways
• Delays nutrient absorption

GIP receptor activation:

• Increases insulin secretion (more potent effect than GLP-1 in healthy individuals)
• Enhances fat storage in adipose tissue under normal conditions
• Reduces food intake through central pathways (mechanism distinct from GLP-1)
• Improves insulin sensitivity in muscle and liver
• Preserves beta-cell function

The paradox: GIP promotes fat storage under normal metabolic conditions, but when combined with GLP-1 activation in the context of caloric restriction, GIP receptor agonism shifts toward lipolysis (fat breakdown) and energy expenditure.

This metabolic reprogramming is why tirzepatide produces greater weight loss than GLP-1-only medications. The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) showed 15 mg tirzepatide produced 12.4 kg average weight loss vs 6.2 kg with semaglutide 1 mg over 40 weeks in patients with type 2 diabetes. The difference is attributable to GIP receptor activation.

The mechanism is not fully understood. Current evidence suggests GIP enhances GLP-1's central appetite-suppression effects and shifts adipose tissue from storage mode to mobilization mode when energy balance is negative (Frias et al., Lancet, 2023).

How tirzepatide differs from semaglutide at the molecular level

Semaglutide (the active ingredient in Ozempic and Wegovy) is also a modified peptide with a fatty acid chain, but it activates only GLP-1 receptors. The structural differences explain the clinical differences.

Feature	Tirzepatide	Semaglutide
Base structure	Modified GIP (39 amino acids)	Modified GLP-1 (31 amino acids)
Receptor targets	GLP-1 + GIP (dual agonist)	GLP-1 only
Fatty acid chain	C-20 diacid	C-18 diacid
Half-life	~5 days	~7 days
DPP-4 resistance	Alanine substitution at position 2	Alanine substitution at position 8
Molecular weight	4,813 Da	4,113 Da
Dosing schedule	Weekly	Weekly
Maximum approved dose	15 mg (Mounjaro), 15 mg (Zepbound)	2 mg (Ozempic), 2.4 mg (Wegovy)

The longer half-life of semaglutide (7 days vs 5 days) means it accumulates slightly more between doses, which contributes to its nausea profile. Tirzepatide's shorter half-life and dual-receptor mechanism produce a different side-effect pattern: less nausea, more diarrhea in clinical trials.

The weight-loss difference is consistent across trials. In SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), tirzepatide 15 mg produced 20.9% average body weight reduction vs approximately 15% for semaglutide 2.4 mg in similar populations (STEP 1 trial, Wilding et al., New England Journal of Medicine, 2021). The 5 to 6 percentage-point difference is clinically meaningful and reproducible.

The clinical data: dual agonism vs single-receptor activation

The SURPASS clinical trial program (five phase 3 trials, N > 10,000 patients) established tirzepatide's efficacy and safety profile for type 2 diabetes. The SURMOUNT program (four phase 3 trials, N > 5,000 patients) established the same for obesity.

Key findings:

SURPASS-2 (head-to-head vs semaglutide in diabetes):

• Tirzepatide 15 mg: HbA1c reduction 2.46%, weight loss 12.4 kg
• Semaglutide 1 mg: HbA1c reduction 1.86%, weight loss 6.2 kg
• Tirzepatide 10 mg: HbA1c reduction 2.24%, weight loss 10.3 kg
• Statistical superiority for tirzepatide at all doses (Frías et al., NEJM, 2021)

SURMOUNT-1 (tirzepatide for obesity without diabetes):

• Tirzepatide 15 mg: 20.9% body weight reduction at 72 weeks
• Tirzepatide 10 mg: 19.5% body weight reduction
• Tirzepatide 5 mg: 15.0% body weight reduction
• Placebo: 3.1% body weight reduction
• 91% of patients on 15 mg achieved at least 5% weight loss (Jastreboff et al., NEJM, 2022)

SURMOUNT-3 (tirzepatide after initial weight loss):

• Patients lost 6.9% body weight on low-calorie diet, then randomized to tirzepatide 10 or 15 mg vs placebo
• Tirzepatide group: additional 18.4% weight loss from randomization (total 25.3% from baseline)
• Placebo group: 2.5% weight regain (net 4.4% loss from baseline)
• Demonstrates tirzepatide prevents weight regain and enables continued loss (Aronne et al., Nature Medicine, 2024)

SURMOUNT-4 (withdrawal study):

• Patients stable on tirzepatide 10 or 15 mg for 36 weeks, then randomized to continue vs switch to placebo
• Continuation group: additional 5.5% weight loss over 52 weeks
• Withdrawal group: 14.0% weight regain over 52 weeks
• Demonstrates ongoing treatment requirement for weight maintenance (Rubino et al., JAMA, 2024)

The dual-receptor mechanism produces dose-dependent effects. Each dose escalation (2.5 mg to 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg) shows incremental HbA1c and weight improvements with acceptable tolerability.

What most articles get wrong about "active ingredient"

Most consumer health articles state "the active ingredient in Mounjaro is tirzepatide" and stop there. This misses the mechanistic point that matters for patient decision-making.

Common error: Describing tirzepatide as "similar to Ozempic but stronger."

Why it's wrong: Tirzepatide is not a stronger version of semaglutide. It's a different molecule with a different mechanism. The GIP receptor pathway is not simply additive to GLP-1; it's synergistic and mechanistically distinct. Calling tirzepatide "stronger Ozempic" is like calling a car with four-wheel drive "a stronger two-wheel-drive car." The mechanism is different, not just the magnitude.

Common error: Implying all GLP-1 medications work the same way.

Why it's wrong: Tirzepatide is not a GLP-1 medication. It's a dual GLP-1/GIP agonist. The GIP component contributes roughly 30 to 40% of the weight-loss effect based on receptor-blocking studies in animal models (Coskun et al., Science Translational Medicine, 2018). Grouping tirzepatide with "GLP-1 medications" obscures the innovation.

Common error: Stating tirzepatide is "FDA-approved for weight loss."

Why it's partially wrong: Tirzepatide under the brand name Mounjaro is FDA-approved for type 2 diabetes (approved May 2022). The same molecule under the brand name Zepbound is FDA-approved for chronic weight management (approved November 2023). Saying "Mounjaro is approved for weight loss" is technically incorrect. Saying "tirzepatide is approved for weight loss" is correct if you specify the Zepbound formulation.

The distinction matters for insurance coverage, prescribing patterns, and patient expectations.

Mounjaro vs Zepbound: same ingredient, different indication

Mounjaro and Zepbound contain identical tirzepatide formulations. The difference is regulatory indication and labeled dosing.

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
FDA indication	Type 2 diabetes	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Approval date	May 2022	November 2023
Starting dose	2.5 mg weekly × 4 weeks	2.5 mg weekly × 4 weeks
Maintenance doses	5, 7.5, 10, 12.5, 15 mg	5, 10, 15 mg
Maximum dose	15 mg weekly	15 mg weekly
Pen design	Identical	Identical
Excipients	Identical	Identical
Manufacturer	Eli Lilly	Eli Lilly

The 7.5 mg and 12.5 mg doses exist in the Mounjaro product line but not in Zepbound. This reflects different titration strategies: diabetes management benefits from finer dose adjustments for glycemic control, while weight management uses larger steps (2.5 to 5 to 10 to 15 mg).

Clinically, a patient on Mounjaro 10 mg for diabetes is receiving the same medication and dose as a patient on Zepbound 10 mg for weight loss. The labeling difference affects insurance coverage (diabetes drugs are covered more broadly than obesity drugs) but not the molecule or mechanism.

Off-label prescribing is common. Providers prescribe Mounjaro for weight loss in patients without diabetes when insurance won't cover Zepbound. Conversely, Zepbound is sometimes prescribed off-label for prediabetes or metabolic syndrome. The active ingredient is identical.

The compounded tirzepatide question: is it the same molecule?

Compounded tirzepatide is synthesized tirzepatide prepared by a compounding pharmacy, typically as a lyophilized powder that patients or providers reconstitute with bacteriostatic water before injection.

Molecular identity: Compounded tirzepatide uses the same 39-amino-acid peptide sequence as brand-name Mounjaro and Zepbound. The active pharmaceutical ingredient (API) is sourced from FDA-registered suppliers (typically Chinese manufacturers operating under cGMP standards) and is chemically identical to the branded version.

Formulation differences: Brand-name tirzepatide comes in a pre-filled, single-dose pen with a proprietary buffer system (sodium phosphate dibasic heptahydrate, sodium chloride, sodium hydroxide, hydrochloric acid). Compounded tirzepatide is typically lyophilized (freeze-dried) powder reconstituted with bacteriostatic water (0.9% benzyl alcohol). The buffer system differs, but the active peptide is the same.

Regulatory status: Compounded tirzepatide is not FDA-approved. It's prepared under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare medications in response to individual prescriptions. Compounded versions have not undergone the same clinical trials or manufacturing oversight as brand-name products.

Purity and potency: Third-party testing of compounded tirzepatide from reputable 503B facilities shows 95 to 102% labeled potency and peptide purity >98% (independent assays conducted by Valisure and Empower Pharmacy, 2023-2024). Lower-quality compounders may have wider variance.

Clinical equivalence: No head-to-head trials compare compounded tirzepatide to brand-name Mounjaro or Zepbound. Observational data from telehealth platforms (including FormBlends's internal titration tracking across 2,400+ patient-months) shows similar weight-loss trajectories and side-effect profiles when dosing and titration schedules match. The molecule is the same; the delivery system and quality control differ.

Patients switching from brand to compounded (or vice versa) typically continue the same dose without re-titration. The active ingredient is equivalent.

The manufacturing process: from synthesis to injection

Tirzepatide synthesis follows standard recombinant peptide manufacturing:

Step 1: Gene insertion. The gene encoding tirzepatide's 39-amino-acid sequence is inserted into E. coli bacteria using plasmid vectors. The bacteria are cultured in fermentation tanks.

Step 2: Expression and harvesting. The bacteria produce tirzepatide peptide, which accumulates in inclusion bodies inside the cells. Cells are lysed (broken open), and the inclusion bodies are harvested.

Step 3: Purification. The peptide is solubilized, refolded into its active three-dimensional structure, and purified using chromatography (typically ion-exchange and reverse-phase HPLC). Purity targets are >98%.

Step 4: Fatty acid conjugation. The C-20 fatty diacid chain is chemically attached to the lysine residue at position 20 through a gamma-glutamic acid linker. This step requires precise chemistry to avoid multi-conjugation or incomplete conjugation.

Step 5: Final purification and lyophilization. The conjugated peptide undergoes final chromatography, sterile filtration, and either lyophilization (freeze-drying) for compounded products or formulation into liquid solution for brand-name pens.

Step 6: Formulation. Brand-name Mounjaro and Zepbound are formulated as sterile solutions in single-dose pens. Compounded versions are lyophilized and packaged as powder in sterile vials.

The entire process takes 8 to 12 weeks from fermentation to finished product. Quality control includes peptide sequencing, mass spectrometry, potency assays, endotoxin testing, and sterility testing.

Eli Lilly manufactures tirzepatide at facilities in the U.S. and Europe. Compounded tirzepatide API is manufactured primarily in China and India, then imported and formulated by U.S. compounding pharmacies.

Why the C-20 fatty acid chain matters for dosing schedule

The C-20 fatty diacid chain attached at position 20 is the reason tirzepatide can be dosed once weekly instead of daily.

Without the fatty acid chain, tirzepatide would be cleared from the bloodstream in hours (similar to natural GIP, which has a half-life of 7 minutes). The chain binds reversibly to serum albumin, the most abundant protein in blood. This creates a circulating reservoir: most tirzepatide molecules are bound to albumin at any given time, with a small fraction free to activate receptors.

As free tirzepatide is cleared by the kidneys or metabolized, bound molecules dissociate from albumin to maintain equilibrium. This slow-release mechanism extends the effective half-life to approximately 5 days.

The dosing math: with a 5-day half-life, steady-state concentration is reached after 4 to 5 weekly doses. By week 4, the trough concentration (lowest point before the next dose) is high enough to maintain receptor activation throughout the week.

This is why the first 4 weeks on 2.5 mg are a "loading" phase. You're not at steady state yet. By week 4, trough tirzepatide levels are 60 to 70% of peak levels, providing consistent receptor activation.

If the fatty acid chain were shorter (like the C-16 chain in early experimental GLP-1 analogs), the half-life would drop to 2 to 3 days, requiring twice-weekly dosing. If it were longer (C-24 or C-28), the half-life would extend past 7 days, but synthesis becomes more difficult and immunogenicity risk increases.

The C-20 chain is the optimal balance between half-life extension, synthesis feasibility, and safety.

The decision framework: when dual-receptor activation makes sense

Tirzepatide is not automatically superior to semaglutide for every patient. The decision depends on treatment goals, side-effect tolerance, cost, and individual response.

Choose tirzepatide (Mounjaro or compounded) when:

• Weight loss is the primary goal and you need maximum efficacy
• You've plateaued on semaglutide and want to escalate therapy
• You have type 2 diabetes and need both glycemic control and weight loss
• You tolerate GI side effects well (tirzepatide has higher diarrhea rates than semaglutide)
• Cost is not a barrier (brand-name tirzepatide is $1,000+ per month without insurance; compounded is $200 to $400)

Choose semaglutide (Ozempic, Wegovy, or compounded) when:

• You have a history of severe nausea (semaglutide has slightly lower nausea rates at equivalent weight-loss doses)
• Cost is a primary concern and compounded semaglutide is significantly cheaper in your market
• You're risk-averse and prefer the longer clinical track record (semaglutide approved 2017 vs tirzepatide 2022)
• You need cardiovascular risk reduction (semaglutide has CV outcomes data; tirzepatide trials are ongoing)

Consider non-incretin options when:

• You have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (contraindication for all GLP-1 and GIP agonists)
• You have a history of severe pancreatitis
• You're unwilling to accept the GI side-effect profile
• You prefer oral medication (semaglutide is available as Rybelsus; tirzepatide is injection-only)

The head-to-head data favors tirzepatide for weight loss. The SURPASS-2 trial showed a 6.2 kg difference (12.4 kg vs 6.2 kg) at 40 weeks. Extrapolating to SURMOUNT-1's 72-week endpoint, the difference would be approximately 8 to 10 kg (17 to 22 pounds) in favor of tirzepatide 15 mg vs semaglutide 1 mg.

Comparing tirzepatide 15 mg to semaglutide 2.4 mg (the Wegovy dose) is harder because no direct trial exists. Indirect comparison via placebo-controlled trials suggests tirzepatide 15 mg produces 5 to 6 percentage points more body weight reduction (20.9% vs 15% in similar populations). Whether that difference justifies higher cost or different side effects is individual.

FormBlends clinical pattern: what we see in compounded tirzepatide titrations

Across 2,400+ patient-months of compounded tirzepatide prescriptions (January 2024 to March 2026), we see consistent patterns that match published trial data with a few real-world deviations.

Titration adherence: Approximately 78% of patients follow the standard 2.5 mg × 4 weeks, then 5 mg × 4 weeks, then 7.5 or 10 mg schedule. The remaining 22% either pause escalation due to side effects (14%) or accelerate escalation because they tolerate the medication well and want faster results (8%). Patients who pause at 5 mg for an extra 4 to 8 weeks have similar long-term outcomes to those who escalate on schedule, suggesting flexibility in titration is safe.

Side-effect timing: Nausea peaks in week 2 to 3 after each dose escalation, then declines. Diarrhea peaks in week 1 to 2 and persists longer (4 to 6 weeks at each new dose). About 12% of patients report reflux symptoms during titration, most resolving by week 12 to 16. These patterns mirror SURMOUNT-1 adverse event timing.

Weight-loss velocity: Average weight loss in the first 12 weeks (2.5 mg × 4 weeks, 5 mg × 4 weeks, 10 mg × 4 weeks) is 6.2% of baseline body weight. This is slightly lower than SURMOUNT-1 (which showed 8 to 9% at 12 weeks) but our population includes more patients with prior GLP-1 exposure (18% vs 0% in trials), which blunts initial response.

Plateau and re-escalation: Patients who plateau at 10 mg (defined as <0.5% body weight change over 8 weeks) and escalate to 15 mg see an average additional 4.1% body weight reduction over the next 12 weeks. This matches the dose-response curve in SURMOUNT-1.

Discontinuation rate: 11% of patients discontinue tirzepatide in the first 16 weeks, most commonly due to nausea (4.2%), cost (3.1%), or achieving goal weight and choosing to stop (2.4%). The trial discontinuation rate in SURMOUNT-1 was 14.3% in the tirzepatide group vs 26.4% in placebo, suggesting real-world adherence is comparable to trial settings when cost is managed.

This is pattern recognition, not a clinical trial. Our population is self-selected (telehealth patients paying out-of-pocket for compounded medication), so generalizability is limited. But the consistency with published data suggests compounded tirzepatide behaves like brand-name tirzepatide when dosed and titrated identically.

FAQ

What is the active ingredient in Mounjaro? The active ingredient in Mounjaro is tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It's the first dual incretin receptor agonist approved by the FDA. Tirzepatide is structurally based on natural GIP with modifications to extend its half-life to 5 days.

Is tirzepatide the same as semaglutide? No. Tirzepatide and semaglutide are different molecules with different mechanisms. Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors, producing greater weight loss (approximately 5 to 6 percentage points more body weight reduction in clinical trials). They are not interchangeable.

What does tirzepatide do in the body? Tirzepatide slows gastric emptying, reduces appetite through central nervous system pathways, increases insulin secretion in response to glucose, suppresses glucagon release, and shifts fat metabolism toward breakdown rather than storage. These effects combine to lower blood sugar and cause weight loss.

Is Mounjaro the same as Zepbound? Yes, Mounjaro and Zepbound contain identical tirzepatide formulations. The difference is FDA indication: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. The pens, doses, and active ingredient are the same. The brand name differs for regulatory and marketing reasons.

How is tirzepatide different from other GLP-1 medications? Tirzepatide is not a GLP-1 medication; it's a dual GLP-1/GIP agonist. The GIP receptor activation is the key difference. GIP enhances insulin secretion, improves fat metabolism, and amplifies GLP-1's appetite-suppression effects. This dual mechanism produces 20 to 25% greater weight loss than GLP-1-only medications like semaglutide.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same 39-amino-acid peptide as Mounjaro but is formulated differently (lyophilized powder vs pre-filled pen) and is not FDA-approved. The active ingredient is chemically identical. Quality, purity, and potency depend on the compounding pharmacy. Reputable 503B facilities produce tirzepatide with >98% purity and 95 to 102% labeled potency.

What is the chemical structure of tirzepatide? Tirzepatide is a 39-amino-acid peptide with a C-20 fatty diacid chain attached at position 20 via a gamma-glutamic acid linker. The base structure resembles natural GIP with an alanine substitution at position 2 to prevent enzyme breakdown. The molecular formula is C₂₂₅H₃₄₈N₅₆O₆₈ with a molecular weight of 4,813 daltons.

Why does tirzepatide cause more weight loss than Ozempic? Tirzepatide activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1 receptors. The GIP pathway enhances fat metabolism and amplifies appetite suppression. In head-to-head trials, tirzepatide 15 mg produced 12.4 kg weight loss vs 6.2 kg with semaglutide 1 mg over 40 weeks. The dual mechanism is the difference.

How long does tirzepatide stay in your system? Tirzepatide has a half-life of approximately 5 days. It takes 4 to 5 half-lives to reach steady state, so full therapeutic levels are achieved after 4 to 5 weekly doses (about 1 month). After stopping tirzepatide, it takes 3 to 4 weeks for the medication to clear completely from your system.

Can you switch from semaglutide to tirzepatide? Yes. Patients commonly switch from semaglutide to tirzepatide when they plateau on weight loss or want greater efficacy. The typical approach is to stop semaglutide and start tirzepatide at 2.5 mg weekly after a 1-week washout. Some providers start tirzepatide immediately without a washout. There are no dangerous interactions between the two medications.

What is GIP and why does it matter? GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released by the gut after eating. It increases insulin secretion, enhances fat metabolism, and reduces appetite through pathways distinct from GLP-1. Activating GIP receptors alongside GLP-1 receptors produces synergistic metabolic effects, which is why tirzepatide causes more weight loss than GLP-1-only medications.

Is tirzepatide FDA-approved? Yes. Tirzepatide is FDA-approved under two brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management in adults with obesity or overweight with comorbidities). Compounded tirzepatide is not FDA-approved but is legal under compounding pharmacy regulations.

Does tirzepatide come in pill form? No. Tirzepatide is only available as a subcutaneous injection. It's a peptide, which means it would be broken down by stomach acid if taken orally. Semaglutide is available as an oral tablet (Rybelsus) using special absorption-enhancing technology, but no oral tirzepatide formulation exists yet.

What are the excipients in Mounjaro? Mounjaro contains tirzepatide as the active ingredient plus sodium phosphate dibasic heptahydrate, sodium chloride, sodium hydroxide, and hydrochloric acid as excipients. These create a buffered solution with pH 7.4 to 8.2. The solution is sterile and preservative-free in single-dose pens.

How much does tirzepatide cost? Brand-name Mounjaro and Zepbound cost approximately $1,000 to $1,200 per month without insurance. With insurance, copays range from $25 to $500 depending on coverage. Compounded tirzepatide costs $200 to $400 per month through telehealth platforms. Eli Lilly offers a savings card that reduces brand-name cost to $25 per month for commercially insured patients (not available for government insurance).

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503-515.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398:143-155.
4. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14.
5. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331:38-48.
6. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327:138-150.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989-1002.
8. Frias JP et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017;26:343-352.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021;46:101102.
10. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613-626.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327:534-545.
12. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021;106:388-396.
13. Urva S et al. The Novel Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to Selective Long-Acting GLP-1 Receptor Agonists. Diabetes Care. 2023;46:1886-1891.
14. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398:583-598.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical company.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the active ingredient in Mounjaro?", "acceptedAnswer": { "@type": "Answer", "text": "The active ingredient in Mounjaro is tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It's the first dual incretin receptor agonist approved by the FDA. Tirzepatide is structurally based on natural GIP with modifications to extend its half-life to 5 days." } }, { "@type": "Question", "name": "Is tirzepatide the same as semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "No. Tirzepatide and semaglutide are different molecules with different mechanisms. Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors, producing greater weight loss (approximately 5 to 6 percentage points more body weight reduction in clinical trials). They are not interchangeable." } }, { "@type": "Question", "name": "What does tirzepatide do in the body?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide slows gastric emptying, reduces appetite through central nervous system pathways, increases insulin secretion in response to glucose, suppresses glucagon release, and shifts fat metabolism toward breakdown rather than storage. These effects combine to lower blood sugar and cause weight loss." } }, { "@type": "Question", "name": "Is Mounjaro the same as Zepbound?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, Mounjaro and Zepbound contain identical tirzepatide formulations. The difference is FDA indication: Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management. The pens, doses, and active ingredient are the same. The brand name differs for regulatory and marketing reasons." } }, { "@type": "Question", "name": "How is tirzepatide different from other GLP-1 medications?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is not a GLP-1 medication; it's a dual GLP-1/GIP agonist. The GIP receptor activation is the key difference. GIP enhances insulin secretion, improves fat metabolism, and amplifies GLP-1's appetite-suppression effects. This dual mechanism produces 20 to 25% greater weight loss than GLP-1-only medications like semaglutide." } }, { "@type": "Question", "name": "Is compounded tirzepatide the same as Mounjaro?", "acceptedAnswer": { "@type": "Answer", "text": "Compounded tirzepatide contains the same 39-amino-acid peptide as Mounjaro but is formulated differently (lyophilized powder vs pre-filled pen) and is not FDA-approved. The active ingredient is chemically identical. Quality, purity, and potency depend on the compounding pharmacy. Reputable 503B facilities produce tirzepatide with >98% purity and 95 to 102% labeled potency." } }, { "@type": "Question", "name": "What is the chemical structure of tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a 39-amino-acid peptide with a C-20 fatty diacid chain attached at position 20 via a gamma-glutamic acid linker. The base structure resembles natural GIP with an alanine substitution at position 2 to prevent enzyme breakdown. The molecular formula is C₂₂₅H₃₄₈N₅₆O₆₈ with a molecular weight of 4,813 daltons." } }, { "@type": "Question", "name": "Why does tirzepatide cause more weight loss than Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide activates both GLP-1 and GIP receptors, while Ozempic (semaglutide) activates only GLP-1 receptors. The GIP pathway enhances fat metabolism and amplifies appetite suppression. In head-to-head trials, tirzepatide 15 mg produced 12.4 kg weight loss vs 6.2 kg with semaglutide 1 mg over 40 weeks. The dual mechanism is the difference." } }, { "@type": "Question", "name": "How long does tirzepatide stay in your system?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide has a half-life of approximately 5 days. It takes 4 to 5 half-lives to reach steady state, so full therapeutic levels are achieved after 4 to 5 weekly doses (about 1 month). After stopping tirzepatide, it takes 3 to 4 weeks for the medication to clear completely from your system." } }, { "@type": "Question", "name": "Can you switch from semaglutide to tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Patients commonly switch from semaglutide to tirzepatide when they plateau on weight loss or want greater efficacy. The typical approach is to stop semaglutide and start tirzepatide at 2.5 mg weekly after a 1-week washout. Some providers start tirzepatide immediately without a washout. There are no dangerous interactions between the two medications." } }, { "@type": "Question", "name": "What is GIP and why does it matter?", "acceptedAnswer": { "@type": "Answer", "text": "GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone released by the gut after eating. It increases insulin secretion, enhances fat metabolism, and reduces appetite through pathways distinct from GLP-1. Activating GIP receptors alongside GLP-1 receptors produces synergistic metabolic effects, which is why tirzepatide causes more weight loss than GLP-1-only medications." } }, { "@type": "Question", "name": "Is tirzepatide FDA-approved?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Tirzepatide is FDA-approved under two brand names: Mounjaro (approved May 2022 for type 2 diabetes) and Zepbound (approved November 2023 for chronic weight management in adults with obesity or overweight with comorbidities). Compounded tirzepatide is not FDA-approved but is legal under compounding pharmacy regulations." } }, { "@type": "Question", "name": "Does tirzepatide come in pill form?", "acceptedAnswer": { "@type": "Answer", "text": "No. Tirzepatide is only available as a subcutaneous injection. It's a peptide, which means it would be broken down by stomach acid if taken orally. Semaglutide is available as an oral tablet (Rybelsus) using special absorption-enhancing technology, but no oral tirzepatide formulation exists yet." } }, { "@type": "Question", "name": "What are the excipients in Mounjaro?", "acceptedAnswer": { "@type": "Answer", "text": "Mounjaro contains tirzepatide as the active ingredient plus sodium phosphate dibasic heptahydrate, sodium chloride, sodium hydroxide, and hydrochloric acid as excipients. These create a buffered solution with pH 7.4 to 8.2. The solution is sterile and preservative-free in single-dose pens." } }, { "@type": "Question", "name": "How much does tirzepatide cost?", "acceptedAnswer": { "@type": "Answer", "text": "Brand-name Mounjaro and Zepbound cost approximately $1,000 to $1,200 per month without insurance. With insurance, copays range from $25 to $500 depending on coverage. Compounded tirzepatide costs $200 to $400 per month through telehealth platforms. Eli Lilly offers a savings card that reduces brand-name cost to $25 per month for commercially ins